ADC Therapeutics Halts Zynlonta Trial Following FDA Hold and Patient Deaths

ADC Therapeutics has announced the discontinuation of a mid-stage study of Zynlonta, a treatment for large B cell lymphoma, in unfit or frail patients following seven patient deaths. The decision comes after the company voluntarily paused enrollment in the study, and the FDA issued a partial hold to stop further enrollment.